[{"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 202, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gregory A. Demopulos M.D.", "age": 66, "title": "Co-Founder, Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1912408, "exercisedValue": 0, "unexercisedValue": 5469956}, {"maxAge": 1, "name": "Mr. David J. Borges", "age": 61, "title": "VP of Finance, Chief Accounting Officer & Treasurer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 693676, "exercisedValue": 0, "unexercisedValue": 259606}, {"maxAge": 1, "name": "Mr. Peter B. Cancelmo J.D.", "age": 46, "title": "VP, General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 651481, "exercisedValue": 0, "unexercisedValue": 720169}, {"maxAge": 1, "name": "Dr. Pamela Pierce Palmer M.D., Ph.D.", "age": 62, "title": "Co-Founder", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. George A. Gaitanaris M.D., Ph.D.", "age": 68, "title": "Chief Scientific Officer & VP of Science", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter W. Williams", "age": 57, "title": "Vice President of Human Resources", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Catherine A. Melfi Ph.D.", "age": 66, "title": "Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nadia  Dac", "age": 55, "title": "VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Grauer M.D.", "age": 64, "title": "VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David W. Ghesquiere", "age": 58, "title": "VP & Chief Business Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 6, "overallRisk": 7, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 13.45, "open": 13.66, "dayLow": 12.45, "dayHigh": 14.25, "regularMarketPreviousClose": 13.45, "regularMarketOpen": 13.66, "regularMarketDayLow": 12.45, "regularMarketDayHigh": 14.25, "payoutRatio": 0.0, "beta": 2.383, "forwardPE": 25.664207, "volume": 4552471, "regularMarketVolume": 4552471, "averageVolume": 4722738, "averageVolume10days": 4477420, "averageDailyVolume10Day": 4477420, "bid": 6.63, "ask": 11.16, "bidSize": 2, "askSize": 2, "marketCap": 885546688, "fiftyTwoWeekLow": 2.95, "fiftyTwoWeekHigh": 17.65, "allTimeHigh": 30.23, "allTimeLow": 0.92, "fiftyDayAverage": 10.199, "twoHundredDayAverage": 6.16655, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1212900736, "profitMargins": 0.0, "floatShares": 68200570, "sharesOutstanding": 70900459, "sharesShort": 13919634, "sharesShortPriorMonth": 13353498, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.19629999, "heldPercentInsiders": 0.02787, "heldPercentInstitutions": 0.46635, "shortRatio": 8.74, "shortPercentOfFloat": 0.2037, "impliedSharesOutstanding": 70900459, "bookValue": -3.146, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -121239000, "trailingEps": -2.02, "forwardEps": 0.48667, "enterpriseToEbitda": -9.45, "52WeekChange": 0.4209329, "SandP52WeekChange": 0.19362879, "quoteType": "EQUITY", "currentPrice": 12.49, "targetHighPrice": 40.0, "targetLowPrice": 36.0, "targetMeanPrice": 38.0, "targetMedianPrice": 38.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 36085000, "totalCashPerShare": 0.509, "ebitda": -128345000, "totalDebt": 363439008, "quickRatio": 0.532, "currentRatio": 0.889, "returnOnAssets": -0.32406, "grossProfits": -38460000, "freeCashflow": -71538128, "operatingCashflow": -105232000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "OMER", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1768006797, "regularMarketTime": 1767992401, "exchange": "NGM", "messageBoardId": "finmb_32388", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1255008600000, "shortName": "Omeros Corporation", "longName": "Omeros Corporation", "regularMarketChangePercent": -7.13755, "regularMarketPrice": 12.49, "marketState": "CLOSED", "postMarketChangePercent": 1.2714182, "postMarketPrice": 12.6488, "postMarketChange": 0.15880013, "regularMarketChange": -0.96, "regularMarketDayRange": "12.45 - 14.25", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 4722738, "fiftyTwoWeekLowChange": 9.54, "fiftyTwoWeekLowChangePercent": 3.2338982, "fiftyTwoWeekRange": "2.95 - 17.65", "fiftyTwoWeekHighChange": -5.16, "fiftyTwoWeekHighChangePercent": -0.29235128, "fiftyTwoWeekChangePercent": 42.09329, "earningsTimestamp": 1763067600, "earningsTimestampStart": 1763067600, "earningsTimestampEnd": 1763067600, "earningsCallTimestampStart": 1763069400, "earningsCallTimestampEnd": 1763069400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.02, "epsForward": 0.48667, "epsCurrentYear": -1.2525, "priceEpsCurrentYear": -9.972055, "fiftyDayAverageChange": 2.2909994, "fiftyDayAverageChangePercent": 0.2246298, "twoHundredDayAverageChange": 6.3234496, "twoHundredDayAverageChangePercent": 1.0254437, "priceToBook": -3.970121, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "displayName": "Omeros", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]